Areas for improvement in the current care and treatment of dry eye disease
Authors:
- 15 April 2025
- journal article
- Published by Taylor & Francis in Expert Review of Ophthalmology
- p. 1-11
Abstract
No abstract availableThis publication has 139 references indexed in Scilit:
- Efficacy and safety of a multi-action tear substitute based on 0.15% cross-linked hyaluronic acid, 3% trehalose and liposomes with stearylamine: A randomized, single-mask, controlled studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2025
- Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye DiseaseJAMA Ophthalmology, 2023
- Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese PatientsJAMA Ophthalmology, 2023
- Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic LandscapeOphthalmology and Therapy, 2023
- Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side EffectsThe Patient - Patient-Centered Outcomes Research, 2022
- Association of the Indoor Environment With Dry Eye MetricsJAMA Ophthalmology, 2020
- Evaluating Patient Experiences in Dry Eye Disease Through Social Media Listening ResearchOphthalmology and Therapy, 2019
- Development and Validation of the Dry Eye–Related Quality-of-Life Score QuestionnaireJAMA Ophthalmology, 2013
- Dry Eye Disease: Impact on Quality of Life and VisionCurrent Ophthalmology Reports, 2013
- Effect of smoking on tear proteinsGraefe's Archive for Clinical and Experimental Ophthalmology, 2002